David-Alexandre C. Gros, M.D.

David-Alexandre C. Gros, M.D.

Chief Executive OfficeratEledon Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-43% from the year before · Eledon Pharmaceuticals stock -63.3% the same year

David-Alexandre C. Gros, M.D. was paid $3.2M in FY2025 (Dec), down 43%. Eledon Pharmaceuticals stock fell 63.3% that year.

Pay$100 in the stock at the end of FY21 → $34
Pay is from the Summary Compensation Table of each Eledon Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Eledon PharmaceuticalsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -39%
  2. Eliem Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Saint Jean Groupe, S.A.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?